TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20441727

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 17970761

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16652312

Group type: EXPERIMENTAL
Intervention: Improved environmental cleaning measures during period 2
Number of subjects: 748

Group type: COMPARATOR
Intervention: No specific intervention (washout period 3)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Multimodal hand hygiene intervention (period 4)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Environmental cleaning rates
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Hand hygiene adherence
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for VRE acquisition
Number of subjects: 748
Study: 12969704

Group type: EXPERIMENTAL
Intervention: Single IUI
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Double IUI
Number of subjects: 110
Study: 10212110

Group type: EXPERIMENTAL
Intervention: Modified Shuttle Test (MST)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regression equation for VO2peak based on MST distance
Number of subjects: 20
Study: 8942357

Group type: EXPERIMENTAL
Intervention: High-energy-protein supplement given immediately after rehydration
Number of subjects: 34

Group type: COMPARATOR
Intervention: High-energy-protein supplement given 2 weeks after presentation
Number of subjects: 34
Study: 2057036

Group type: EXPERIMENTAL
Intervention: 16-hour nicotine patch (15 +/- 3.5 mg of nicotine in 16 hours)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 289
Study: 3914473

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 gram preoperative dose)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cefoxitin (2 gram preoperative dose and four 2 gram postoperative doses)
Number of subjects: 57
Study: 31733770

Group type: EXPERIMENTAL
Intervention: Modified Sphygmomanometer Test (MST) with fixed stabilization
Number of subjects: 59
Study: 28125252

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Unadjusted NEO-PI-R scales
Number of subjects: 300
Study: 25956151

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing retraining (DBR) intervention over 8 weeks with follow-up at 5 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Attention control group receiving general health information
Number of subjects: 36
Study: 24506529

Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA™)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Thermal balloon ablation (TBall)
Number of subjects: 320
Study: 22344555

Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg
Number of subjects: 20
Study: 20100756

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (core temperatures of 35.5 degrees C, 34.5 degrees C, and 33.5 degrees C) for 48 hours
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (cooling group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Noncooled group (control)
Number of subjects: 15
Study: 17659006

Group type: EXPERIMENTAL
Intervention: 308-nm monochromatic excimer light (MEL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Narrowband UVB phototherapy (NB‐UVB)
Number of subjects: 21
Study: 16185216

Group type: EXPERIMENTAL
Intervention: Five-Day Plan (FDP) - a behavioural group-based treatment programme involving five consecutive evening sessions.
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group - a single session discussing the health effects of smoking.
Number of subjects: 228
Study: 12610193

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study: 14564595

Group type: EXPERIMENTAL
Intervention: Nicardipine (30 microg.kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg.kg(‐1))
Number of subjects: 60
Study: 8800982

Group type: EXPERIMENTAL
Intervention: Continuous ST segment monitoring for 48 hours
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Admission ECG ST depression
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Normal admission ECG
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Maintenance beta blocker treatment
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Transient ischaemia
Number of subjects: 212
Study: 1671795

Group type: EXPERIMENTAL
Intervention: Retinol palmitate (300,000 IU daily for at least 12 months)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Standard observation (control group)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Retinol palmitate
Number of subjects: 283
Study: 6361986

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS) 2-3 mg/kg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50-100 mg/kg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo matching diclofenac
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 45
Study: 29607845

Group type: EXPERIMENTAL
Intervention: Audio aids + Braille
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Audio aids + Tactile models
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Audio aids + Braille + Tactile models
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 27560769

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 66
Study: 25455853

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermittent bolus (IB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both CI and IB
Number of subjects: 16
Study: 23991670

Group type: EXPERIMENTAL
Intervention: GW870086 (1 mg, once-daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21632199

Group type: EXPERIMENTAL
Intervention: NADA Auricular Acupuncture (AA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham Auricular Acupuncture (AA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Treatment setting control
Number of subjects: 101
Study: 18501783

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160-mg/d tablet)
Number of subjects: 24
Study: 17040926

Group type: EXPERIMENTAL
Intervention: Self management programme for arthritis and an education booklet
Number of subjects: 812

Group type: COMPARATOR
Intervention: Education booklet alone
Number of subjects: 812
Study: 14643944

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (0.05% blood alcohol level)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-drug-using participants)
Number of subjects: 0
Study: 11918092

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overbreathe under isocapnic conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral movement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 8927195

Group type: EXPERIMENTAL
Intervention: Emotional management training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Anti-stress therapy
Number of subjects: 16
Study: 1624155

Group type: EXPERIMENTAL
Intervention: Sodium chloride capsules
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose electrolyte solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose polymer solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: No added salt (control)
Number of subjects: 6
Study: 6152088

Group type: EXPERIMENTAL
Intervention: sultosilic acid piperazine salt (A‐585)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 20
Study: 29405548

Group type: EXPERIMENTAL
Intervention: Shuffle stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional stimulation
Number of subjects: 12
Study: 27324280

Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg per infusion for adults >25 years; 0.05 mg/kg for first two infusions and 4 mg for remaining eight infusions for patients aged 18-25 years; 0.05 mg/kg per infusion for younger patients) combined with standard chemotherapy.
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (chemotherapy alone).
Number of subjects: 318
Study: 24211863

Group type: COMPARATOR
Intervention: Conventional implantation (atelocollagen gel at room temperature for 15 minutes)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Preheating (atelocollagen warmed at 41 C for 8 minutes)
Number of subjects: 27
Study: 23764081

Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift
Number of subjects: 206

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 206
Study: 19740072

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18046340

Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion (TA) with normal saline solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (those who declined TA)
Number of subjects: 44
Study: 16388054

Group type: EXPERIMENTAL
Intervention: Shock absorbing insoles (Sorbothane or Poron)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Non-shock absorbing insoles (Saran)
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Sorbothane insoles
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Poron insoles
Number of subjects: 1205
Study: 12077570

Group type: EXPERIMENTAL
Intervention: Adenosine treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study: 10072667

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexnafenodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8545744

Group type: EXPERIMENTAL
Intervention: Single doses of 1,600, 2,400, and 3,200 mg of hypoxoside (standardised Hypoxis plant extract, 200 mg capsules)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple doses of 2,400 mg of hypoxoside (4 capsules 3 times daily for 11 days)
Number of subjects: 24
Study: 2253931

Group type: EXPERIMENTAL
Intervention: Lactitol (36.3 g +/- 5 daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lactulose (38.2 g +/- 19 daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 14
Study: 6155064

Group type: EXPERIMENTAL
Intervention: Acetylprocainamide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30910563

Group type: EXPERIMENTAL
Intervention: Active, intensive, repetitive upper limb training using the SMART Arm device 5 days a week for 5 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual upper limb therapy 5 days a week for 5 weeks
Number of subjects: 50
Study: 28862982

Group type: EXPERIMENTAL
Intervention: 1000 mg metformin administration
Number of subjects: 26
Study: 26144895

Group type: EXPERIMENTAL
Intervention: 10 μg HB vaccine in Group A
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: 5 μg HB vaccine in Group C
Number of subjects: 506

Group type: COMPARATOR
Intervention: 5 μg HB vaccine in Group B
Number of subjects: 506
Study: 23881448

Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Combined physical plus cognitive training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 70
Study: 22509319

Group type: EXPERIMENTAL
Intervention: MTZ-Clind (oral metronidazole 400 mg bid + 2% vaginal clindamycin-cream)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: MTZ-Prob (oral metronidazole 400 mg bid + Lactobacillus acidophilus vaginal-probiotic)
Number of subjects: 450

Group type: COMPARATOR
Intervention: MTZ-Placebo (oral metronidazole 400 mg bid + placebo)
Number of subjects: 450
Study: 20021683

Group type: EXPERIMENTAL
Intervention: Medical Emergency Teams (METs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 0
Study: 17318804

Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted liver resection (RF-R)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clamp-crushing method
Number of subjects: 50
Study: 15385356

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.2 mg/kg based on real body weight (RBW) in Group I (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cisatracurium based on RBW in the control group (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisatracurium based on ideal body weight (IBW) in Group II (n = 10)
Number of subjects: 20
Study: 11251623

Group type: EXPERIMENTAL
Intervention: Rofecoxib (1.5-25.0 mg for 5 consecutive days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10481816

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7604691

Group type: EXPERIMENTAL
Intervention: Chronic female alcoholics
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 2337059

Group type: EXPERIMENTAL
Intervention: Olsalazine 3.0 g/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olsalazine (open label after placebo)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall Olsalazine treatment
Number of subjects: 15
Study: 10328033

Group type: EXPERIMENTAL
Intervention: 720 mg trimethoprim plus 3,600 mg sulfamethoxazole
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3.5 g ampicillin plus 1 g probenecid
Number of subjects: 50
Study: 30692839

Group type: COMPARATOR
Intervention: Instrument-assisted soft tissue mobilization (IASTM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 40
Study: 26848934

Group type: EXPERIMENTAL
Intervention: Bolus calculator (Cb group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Active control (Co group)
Number of subjects: 70
Study: 26131753

Group type: EXPERIMENTAL
Intervention: Arteriovenous coupler therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 0
Study: 23205722

Group type: EXPERIMENTAL
Intervention: Contingency group (n = 35)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Prescription group (n = 32)
Number of subjects: 67
Study: 21309874

Group type: EXPERIMENTAL
Intervention: 30% glucose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 30
Study: 19859935

Group type: EXPERIMENTAL
Intervention: T(1Gd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DeltaR(1)
Number of subjects: 0
Study: 17565920

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15%
Number of subjects: 43
Study: 14579918

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 42
Study: 10375203

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combination of BAP levels and percent BAP change at 6 months
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combination model
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 8887578

Group type: EXPERIMENTAL
Intervention: Tiotropium 10 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tiotropium 40 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tiotropium 80 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1286471

Group type: EXPERIMENTAL
Intervention: Placebo treatment (n = 15)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-placebo control group (n = 9)
Number of subjects: 24
Study: 6130292

Group type: EXPERIMENTAL
Intervention: Naloxone treatment (oral and intravenous)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (large daily doses of laxatives and additional suppositories and enemas)
Number of subjects: 2
Study: 3515468

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g or 2 g once daily for 7-12 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cefotaxime (2 g twice daily for 7-12 days)
Number of subjects: 54
Study: 31727194

Group type: EXPERIMENTAL
Intervention: 3 % glycated milk protein
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 % glycated milk protein
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 % glycated milk protein
Number of subjects: 15
Study: 29748142

Group type: EXPERIMENTAL
Intervention: Direct Expert Feedback (DEF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Asynchronous Unsupervised Video-Enhanced Feedback (UVF)
Number of subjects: 42
Study: 26551403

Group type: EXPERIMENTAL
Intervention: Neurocognitive interventions (cognitive control training and/or transcranial direct current stimulation)
Number of subjects: 0
Study: 25560155

Group type: EXPERIMENTAL
Intervention: Isotonic fluid (0.9% NaCl solution in 5% dextrose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypotonic fluid (0.18% NaCl in 5% dextrose)
Number of subjects: 60
Study: 21938763

Group type: EXPERIMENTAL
Intervention: Mathematics Intervention (40-50 hours over 1 year)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mathematics Intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 57
Study: 21197498

Group type: EXPERIMENTAL
Intervention: Immediate loading (111 implants, 45 patients)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Delayed loading (111 implants, 51 patients)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Immediate implant placement with immediate function (group 1)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Delayed implant placement with immediate function (group 2)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Delayed implant placement with delayed function (group 3)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Delayed implant placement with delayed function (group 4)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Immediate function implants
Number of subjects: 76
Study: 18386572

Group type: EXPERIMENTAL
Intervention: Ningzhi Capsule (NZC) 5 tablets, 3 times a day for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lipanthgl or Simvastatin (control group)
Number of subjects: 70
Study: 15766344

Group type: EXPERIMENTAL
Intervention: Flexiblade laryngoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 100
Study: 14508311

Group type: EXPERIMENTAL
Intervention: AEP-monitored group (AAI-guided administration)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AEP-monitored group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (standard clinical practice)
Number of subjects: 70
Study: 10092691

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, 2 mg/puff, two puffs three times daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (two puffs three times daily)
Number of subjects: 79
Study: 8687370

Group type: EXPERIMENTAL
Intervention: Musical Mood Induction (Depression/Elation)
Number of subjects: 0
Study: 1757042

Group type: EXPERIMENTAL
Intervention: 2% MK-507 with 0.5% hydroxyethylcellulose (HEC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2% MK-507 without HEC
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle with HEC
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle without HEC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2% MK-507 (both formulations)
Number of subjects: 24
Study: 6850464

Group type: EXPERIMENTAL
Intervention: BCG administered orally in patients with resectable colon cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG administered orally in nonrandomized studies of patients with malignant melanoma and stage IV breast carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective stimulation of the immune system with NED 137 in advanced gastrointestinal cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG administered intraperitoneally along with 5-fluorouracil for gastrointestinal cancer
Number of subjects: 0
Study: 30415648

Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bias-contingent Attention Bias Modification (BC-ABM)
Number of subjects: 50
Study: 29621811

Group type: EXPERIMENTAL
Intervention: Injected Vitamin D (300,000 units in 1 cc)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (placebo, 1 cc)
Number of subjects: 100
Study: 26936298

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 49
Study: 24585722

Group type: EXPERIMENTAL
Intervention: Bevacizumab-pemetrexed (500 mg/m2)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Bevacizumab (7.5 mg/kg)
Number of subjects: 376
Study: 22272251

Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIE) (75% VO(2)max)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-Intensity Exercise (LIE) (40% VO(2)max)
Number of subjects: 15
Study: 20873893

Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral (CB) intervention
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 341

Group type: COMPARATOR
Intervention: Supportive expressive intervention
Number of subjects: 341

Group type: COMPARATOR
Intervention: Brochure control
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Group CB participants
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: CB bibliotherapy participants
Number of subjects: 341
Study: 17522988

Group type: EXPERIMENTAL
Intervention: Methylphenidate, gradually increasing dosage over two weeks, followed by a similar two-week period of gradually diminishing dosage.
Number of subjects: 0